Selank: 10MG

£27.99

Purity: ≥ 99%

£27.99

Selank: 10MG

Name: Selank: 10MG
Brand: Pure Grade Labs
Price: 27.99 GBP
Availability: OutOfStock

£27.99

Purity: ≥ 99%

£27.99

NOOTROPIC - Memory, focus & cognitive performance research

ANXIOLYTIC - Anxiety & stress reduction research

IMMUNOMODULATORY - Immune balance & inflammation control research

ENKEPHALIN SYSTEM - Natural pain relief & opioid balance research

Selank (also designated TP-7) is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the V.V. Zakusov Research Institute of Pharmacology. Its sequence - Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) - is based on the naturally occurring immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), a fragment of the IgG antibody heavy chain known for its immunoregulatory activity. The three C-terminal amino acids Pro-Gly-Pro were added specifically to enhance the metabolic stability of the parent sequence, substantially extending its effective half-life compared to tuftsin itself, which is rapidly degraded by plasma peptidases.

Selank has been investigated across a substantial body of preclinical and clinical research for its anxiolytic, nootropic, and immunomodulatory properties. Its reported pharmacological activity spans multiple neurotransmitter systems: it has been shown to interact with GABA-A receptor pathways, inhibit the enzymatic degradation of endogenous enkephalins (endogenous opioid peptides), rapidly upregulate BDNF expression in hippocampal tissue, and modulate the expression of genes involved in serotonergic and dopaminergic neurotransmission. Selank is approved as a drug in Russia and Ukraine for the treatment of generalised anxiety disorder and as a nootropic agent, making it one of the few peptides in this category with a human regulatory approval outside Western markets.

Origin: Structurally derived from tuftsin, a tetrapeptide fragment of the Fc region of IgG antibodies. The C-terminal Pro-Gly-Pro extension is a synthetic modification added to increase metabolic stability and prolong bioactivity in vivo, differentiating Selank from its natural precursor.

Research Context: Approved as a drug in Russia and Ukraine. Studied in clinical trials for generalised anxiety disorder and neurasthenia. Preclinical evidence spans anxiolytic, nootropic, immunomodulatory, and neuroprotective pathways. The majority of research originates from Russian institutions. International independent replication remains limited.

Amino Acid Sequence: H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH

Molecular Formula: C33H57N11O9

Molecular Weight: 751.9 g/mol

Form: Lyophilised Solid

The following summaries are drawn from peer-reviewed publications. Retatrutide's published human evidence base currently consists of Phase 2 data from two RCTs. Phase 3 data is not yet available. Pure Grade Labs does not interpret these findings as evidence of clinical efficacy in humans, and notes that Phase 2 findings must be confirmed in larger Phase 3 trials.

New England Journal of Medicine: Phase 2 obesity trial: Retatrutide 12mg produces 24.2% mean weight loss at 48 weeks in adults with obesity (n=338)

The Lancet: Phase 2 T2D trial: Retatrutide produces 16.9% weight loss and HbA1c reduction of 2.2% over 36 weeks, outperforming dulaglutide (n=281)

Nature Medicine: Retatrutide reduces liver fat by up to 82% in a Phase 2 sub-study of participants with metabolic dysfunction-associated steatotic liver disease (n=98)

References

https://pubmed.ncbi.nlm.nih.gov/38367045/

https://pubmed.ncbi.nlm.nih.gov/37366315/

https://pubmed.ncbi.nlm.nih.gov/37385280/

https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/

https://pmc.ncbi.nlm.nih.gov/articles/PMC11420505/

https://clinicaltrials.gov/study/NCT05936151

Every batch of Selank supplied by Pure Grade Labs is accompanied by a Certificate of Analysis (COA) from an independent third-party analytical laboratory. The COA confirms identity, purity by HPLC, and absence of contaminants. Batch-specific documentation is linked below.

Selank is supplied as a lyophilised (freeze-dried) solid. As a heptapeptide, Selank is relatively stable compared to larger peptides, but requires refrigeration once reconstituted due to its susceptibility to enzymatic degradation in aqueous solution. Follow the specifications below for optimal compound integrity.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow the sealed vial to reach room temperature before opening to minimise moisture introduction from condensation.
Use bacteriostatic water (BAC water) or sterile saline as the reconstitution solvent. Selank is water-soluble and dissolves readily in aqueous solution. Add solvent slowly down the inside wall of the vial.
Gently swirl the vial until fully dissolved. Do not vortex or shake vigorously. Selank reconstitutes easily and does not require prolonged mixing.
Once reconstituted, store at 2-8°C. Use within 7-14 days. Do not freeze reconstituted solution. Avoid repeated freeze-thaw cycles as Selank degrades rapidly in solution compared to the lyophilised form.
Discard if solution appears cloudy, discoloured, or contains particulate matter.

Selank supplied by Pure Grade Labs is intended exclusively for in vitro research and laboratory use. This product is not approved for human or veterinary use by any regulatory authority, including the FDA, MHRA, TGA, or EMA.

This product is not a drug, medicine, or supplement and must not be used as such.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy in humans.
This product must not be administered to humans or animals outside of a licensed research context.
Selank is approved as a pharmaceutical drug in Russia and Ukraine for anxiety disorder treatment. It does not hold approval from the FDA, EMA, MHRA, TGA, or equivalent regulatory authorities in other jurisdictions. Its regulatory status varies by country and purchasers must verify local compliance obligations.
Although Selank's clinical profile has been described as non-habit-forming and free from the dependence and withdrawal effects associated with benzodiazepines, long-term safety data from large-scale international trials is not available.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction.

All product information, research summaries, and study citations presented on this page are provided for informational context only and do not constitute medical advice, endorsement of any treatment, or recommendation for human use.